NCT06673368View on ClinicalTrials.gov

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 25, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
ADHD
Interventions
DRUG

NRCT-101SR, NRCT-202XR

NRCT-101SR in combination with NRCT-202XR or NRCT-202XR alone

Trial Locations (5)

30030

RECRUITING

iResearch Atlanta, Decatur

31405

RECRUITING

CenExel iRS - iResearch Savannah, Savannah

32751

RECRUITING

Accel Research Site-Maitland Clinical Research Unit, Maitland

89128

RECRUITING

Center For Psychiatry and Behavioral Medicine, Las Vegas

02131

RECRUITING

Boston Clinical Trials LLC, Boston

Sponsors

Lead Sponsor

Neurocentria, Inc.
All Listed Sponsors
lead

Neurocentria, Inc.

INDUSTRY

NCT06673368 - A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder | Biotech Hunter | Biotech Hunter